ATE267809T1 - Substituierte 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung - Google Patents

Substituierte 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Info

Publication number
ATE267809T1
ATE267809T1 AT99948791T AT99948791T ATE267809T1 AT E267809 T1 ATE267809 T1 AT E267809T1 AT 99948791 T AT99948791 T AT 99948791T AT 99948791 T AT99948791 T AT 99948791T AT E267809 T1 ATE267809 T1 AT E267809T1
Authority
AT
Austria
Prior art keywords
pyridine
ylamino
diaryl
substituted
compounds
Prior art date
Application number
AT99948791T
Other languages
German (de)
English (en)
Inventor
Reinhard Kirsch
Alfons Enhsen
Heiner Glombik
Werner Kramer
Eugen Falk
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE267809T1 publication Critical patent/ATE267809T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT99948791T 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung ATE267809T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845406A DE19845406C2 (de) 1998-10-02 1998-10-02 Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006933 WO2000020393A1 (de) 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
ATE267809T1 true ATE267809T1 (de) 2004-06-15

Family

ID=7883187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948791T ATE267809T1 (de) 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Country Status (22)

Country Link
US (1) US6596728B1 (enExample)
EP (1) EP1117642B1 (enExample)
JP (1) JP4544746B2 (enExample)
KR (1) KR100609255B1 (enExample)
CN (1) CN1173951C (enExample)
AR (1) AR021845A1 (enExample)
AT (1) ATE267809T1 (enExample)
AU (1) AU757689B2 (enExample)
BR (1) BR9915027B1 (enExample)
CA (1) CA2345985C (enExample)
CZ (1) CZ299569B6 (enExample)
DE (2) DE19845406C2 (enExample)
DK (1) DK1117642T3 (enExample)
ES (1) ES2219066T3 (enExample)
HU (1) HU226688B1 (enExample)
ID (1) ID29249A (enExample)
PL (1) PL205034B1 (enExample)
PT (1) PT1117642E (enExample)
RU (1) RU2224748C2 (enExample)
TR (1) TR200100896T2 (enExample)
WO (1) WO2000020393A1 (enExample)
ZA (1) ZA200102587B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030501A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP1420826A2 (de) * 2001-08-22 2004-05-26 Aventis Pharma Deutschland GmbH Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
ES2633766T3 (es) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico
JP2016514678A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー バレット食道と胃食道逆流性疾患を処置するための胆汁酸再利用阻害剤
KR20230152818A (ko) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
ES2982943T3 (es) 2019-02-12 2024-10-21 Mirum Pharmaceuticals Inc Métodos para aumentar el crecimiento en sujetos pediátricos con hepatopatía colestásica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
SU1194273A3 (ru) * 1981-02-09 1985-11-23 Пфайзер Инк (Фирма) Способ получени пирбутерола или его аналогов
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
DK0557879T3 (da) * 1992-02-22 1997-06-16 Hoechst Ag 4-amino-2-ureido-pyrimidin-5-carboxylsyreamider, fremgangsmåde til deres fremstilling, lægemidler med indhold af disse forbindelser og deres anvendelse
ES2223091T3 (es) * 1997-04-04 2005-02-16 Aventis Pharma Deutschland Gmbh Derivados de propanolamina hipolipidemicos.
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung

Also Published As

Publication number Publication date
CZ299569B6 (cs) 2008-09-03
AU6192699A (en) 2000-04-26
ES2219066T3 (es) 2004-11-16
BR9915027B1 (pt) 2010-09-08
TR200100896T2 (tr) 2001-09-21
DE19845406A1 (de) 2000-04-13
JP2002526530A (ja) 2002-08-20
DE59909606D1 (de) 2004-07-01
BR9915027A (pt) 2001-07-17
PL205034B1 (pl) 2010-03-31
CN1173951C (zh) 2004-11-03
KR100609255B1 (ko) 2006-08-04
WO2000020393A1 (de) 2000-04-13
AU757689B2 (en) 2003-03-06
RU2224748C2 (ru) 2004-02-27
CA2345985A1 (en) 2000-04-13
ID29249A (id) 2001-08-16
HU226688B1 (hu) 2009-06-29
PT1117642E (pt) 2004-09-30
JP4544746B2 (ja) 2010-09-15
CA2345985C (en) 2010-06-29
EP1117642A1 (de) 2001-07-25
HK1051533A1 (en) 2003-08-08
US6596728B1 (en) 2003-07-22
KR20010075496A (ko) 2001-08-09
CZ20011152A3 (cs) 2001-07-11
HUP0103533A3 (en) 2003-01-28
EP1117642B1 (de) 2004-05-26
ZA200102587B (en) 2001-11-05
PL347096A1 (en) 2002-03-25
HUP0103533A2 (hu) 2002-02-28
CN1391558A (zh) 2003-01-15
AR021845A1 (es) 2002-08-07
DE19845406C2 (de) 2001-10-18
DK1117642T3 (da) 2004-08-09

Similar Documents

Publication Publication Date Title
DE59908522D1 (de) Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE266005T1 (de) Arylsubstituierte propanolaminderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE342899T1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE338039T1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50002646D1 (de) Mit zuckerresten substituierte 1,4-benzothiazepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50114874D1 (de) Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE477266T1 (de) Neue thiophenglycosidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE150033T1 (de) N,o-sulfatierte heparosane; verfahren zu deren herstellung und diese enthaltende arzneimittel
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE59806467D1 (de) Benzamidoxim-derivate, zwischenprodukte und verfahren zu deren herstellung und deren verwendung als fungizide
ATE350378T1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE50113328D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE266673T1 (de) Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE232879T1 (de) Erythromycin-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE267825T1 (de) Mit heterocyclen substituierte propanolaminderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE217633T1 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
ATE267809T1 (de) Substituierte 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE69909209D1 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
AT397797B (de) Capsaicin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE211745T1 (de) 10,13,15-trioxatricyclo(9.2.1.1. 9.6)- pentadecanon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE301645T1 (de) Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE209212T1 (de) Aromatische ribose-substituierte derivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel
ATE486083T1 (de) 11-acetyl-12,13-dioxabicyclo 8.2.1 tridecenon- derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69716284D1 (de) Erythromycin-derivate, verfahren zur herstellung und verwendung als arzneimittel
DE59003716D1 (de) Neue diphosphonsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.